Cannara Biotech reports Q2 results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 28 2025
0mins
Source: SeekingAlpha
Financial Performance: Cannara Biotech reported a Q2 2025 GAAP EPS of $0.04, with net revenues increasing by 35% to $26.6 million compared to Q2 2024, attributed to brand growth and product innovations.
Profit Growth: The company's gross profit before fair value adjustments rose 52% to $10.8 million in Q2 2025, leading to an improvement in gross margins to 41%.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
